Carfilzomib, Clinical Trials, T-Cell Lymphoma

Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

This study is completed.

This phase I trial studies the side effects and best dose of carfilzomib in treating patients with relapsed or refractory T-cell lymphoma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Study Type:    Interventional

Study Design:    

Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title:    Phase I Study of Carfilzomib for the Treatment of T-Cell Lymphoma

Conditions:  

Adult Nasal Type Extranodal NK/T-cell Lymphoma
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Peripheral T-cell Lymphoma
Recurrent Adult T-cell Leukemia/Lymphoma                                    

Intervention:  Drug:  carfilzomib          

Phase:  Phase 1

External Link: https://clinicaltrials.gov/show/NCT01336920